PepGen Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
PEPG Nasdaq 8731 https://pepgen.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for PepGen Inc

Best Momentum Stocks to Buy for April 25th - Apr 25th, 2024 2:00 pm
PepGen to Participate in Upcoming Investor Conferences - Mar 13th, 2024 8:05 pm
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy - Mar 13th, 2024 11:00 am
Can PepGen, Inc. (PEPG) Climb 48.62% to Reach the Level Wall Street Analysts Expect? - Mar 12th, 2024 1:55 pm
PepGen, Inc. (PEPG) Upgraded to Buy: What Does It Mean for the Stock? - Mar 11th, 2024 4:00 pm
PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments - Mar 6th, 2024 9:01 pm
PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy - Mar 4th, 2024 12:00 pm
PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1 - Feb 20th, 2024 1:00 pm
PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock - Feb 7th, 2024 12:30 pm
Mary Beth DeLena Joins PepGen as General Counsel and Secretary - Jan 17th, 2024 12:00 pm
Institutions own 24% of PepGen Inc. (NASDAQ:PEPG) shares but private equity firms control 54% of the company - Jan 12th, 2024 10:11 am
PepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping - Jan 8th, 2024 12:00 pm
PepGen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1) - Dec 18th, 2023 1:00 pm
We Think PepGen (NASDAQ:PEPG) Needs To Drive Business Growth Carefully - Dec 2nd, 2023 2:41 pm
PepGen Announces Appointment of Howard Mayer, M.D. to Board of Directors - Nov 15th, 2023 1:00 pm
PepGen Reports Third Quarter 2023 Financial Results and Recent Corporate Developments - Nov 8th, 2023 1:00 pm
PepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1) - Oct 12th, 2023 11:00 am
PepGen Announces Upcoming Presentations at the 28th Annual Congress of the World Muscle Society and the World Congress of Neurology - Sep 27th, 2023 8:16 pm
PepGen Inc. Announces Clearance of CTA by Health Canada to Begin the FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 in Patients with Myotonic Dystrophy Type 1 - Sep 6th, 2023 8:05 pm
PepGen Inc. Presents PGN-EDODM1 Preclinical Data Supporting the Company’s Enhanced Delivery Oligonucleotide Platform and PGN-EDODM1 Program at Two Medical Conferences - Sep 6th, 2023 12:00 pm